$ZSPC

zSpace Expands Immersive Learning with New Studio Capabilities and ScholarLab Biology Simulations Ahead of ISTELive 2026

zSpace, Inc. (OTC: ZSPC) said it is expanding its immersive learning platform ahead of ISTELive 2026. The company announced a new version of zSpace Studio, available now exclusively to zSpace Inspire device customers, with expanded model libraries and improved creation tools. It also plans to add 16 new biology simulations to ScholarLab this fall, with content aligned to high school and middle school standards.

Original reporting
Published Jun 25, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
zSpace Expands Immersive Learning with New Studio Capabilities and ScholarLab Biology Simulations Ahead of ISTELive 2026 — source image
Decision brief

The 30-second read

$ZSPCBullishLow
01

Why it matters

The new Studio release (exclusive to Inspire customers) and additional biology simulations expand the platform’s curriculum coverage for back-to-school, potentially improving educator adoption and student engagement.

02

Market read

Traders get a concrete product roadmap update (Studio enhancements + 16 biology simulations) but no quantified financial impact.

03

What to watch

Because the company is OTC-listed, market reaction may be driven more by liquidity/positioning than by the product roadmap itself.

Relevance 4/10Novelty 4/10Timing: ahead of back-to-school (this fall) and ISTELive 2026 (June 29–July 1)

Background

zSpace provides AR/VR learning solutions; ScholarLab is its simulation application and zSpace Studio is its 3D modeling/creation tool.

Company-level read

Ticker impact

$ZSPCBullishLow confidence
Context

zSpace announces a new zSpace Studio version for Inspire customers and 16 new ScholarLab biology simulations arriving this fall.

Expected impact

Near-term impact likely limited; any reaction would be sentiment/visibility-driven rather than fundamentals.

Evidence & confidence

The article is a promotional product update with no revenue, bookings, or adoption metrics; OTC liquidity also limits signal strength.

Market effects

Highlights ongoing AR/VR education content development, which may modestly support sentiment toward edtech/immersive learning vendors.

No specific regional demand or policy linkage beyond US school adoption framing.

Primarily US education-focused; limited evidence of international expansion in the text.

Counterpoint

Without disclosed customer traction, pricing, or revenue impact, the update may not translate into measurable near-term financial upside.

Key entities

  • zSpace, Inc.

    OTC-listed AR/VR education provider announcing Studio and ScholarLab content expansions.

  • zSpace Inspire

    Device customer base that will receive the updated zSpace Studio version.

  • ScholarLab

    Simulation application receiving 16 new biology simulations this fall.

  • ISTELive 2026

    Educator conference where zSpace will demonstrate the platform (Booth 1333, June 29–July 1).

Related articles

$ZSPCMed

zSpace, Inc. (ZSPC): Results of Operations and Financial Condition

zSpace, Inc. (ZSPC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zspc-20260813xex99d1.htm EX-99.1 Exhibit 99.1 ​ zSpace Reports Second Quarter 2026 Financial Results ​ Margin Expansion Drives Profitability; Strategic Alternatives Review Remains Ongoing ​ SAN JOSE, Calif., August 13, 2026 – zSpace, Inc. (OTC: ZSPC) (“zSpace” or the “C

$ZSPCMedAI 8/10

ZSPC Investor Alert - zSpace, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

Robbins LLP said it is investigating allegations in a securities fraud class action against zSpace, Inc. (NASDAQ: ZSPC) tied to the company’s December 2024 IPO. The complaint alleges the IPO registration materials failed to disclose prior preferred-share communications, an unnamed preferred purchaser, potential litigation risk, and that risk disclosures downplayed litigation. Investors may seek lead-plaintiff status by June 22, 2026.

$ZSPCLowAI 8/10

ZSPC Investor Alert - zSpace, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

Robbins LLP said it is investigating a securities fraud class action against zSpace, Inc. (NASDAQ: ZSPC) tied to the company’s December 2024 IPO. The complaint alleges the IPO registration statement/prospectus omitted issues involving preferred shareholders, an unnamed purchaser, and potential litigation risk. Investors may seek lead-plaintiff status by June 22, 2026.

$RNAMedAI 8/10

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Atrium Therapeutics (Nasdaq: RNA) reported Q2 2026 results for the quarter ended June 30. FDA cleared its IND for ATR 1072 and it launched the Corventis Phase 1/2 trial for PRKAG2 syndrome. Atrium also received a $15 million second milestone payment from Bristol Myers Squibb. Q2 collaboration revenue was $3.0M, R&D $15.3M, G&A $10.3M, cash $263.9M.

$IRENMed

Why Iren Stock Topped the Market on Thursday

Iren (IREN) rose about 3% on Thursday after announcing it delivered a 50-megawatt AI compute deployment at its Childress, Texas campus for Microsoft. The first stage supports a five-year cloud services contract valued at $9.7 billion. Iren said Nvidia granted Exemplar Cloud status to the GB300 NVL72 architecture and reiterated targets of 480 MW in 2026 and 1.2 GW in 2027.

$IPWRMed

Ideal Power advances AI Data center and EV programs in Q2 2026

Ideal Power (IPWR) reported Q2 2026 progress commercializing its B-TRAN solid-state power technology for AI data centers, energy infrastructure, and EVs. It advanced an SSCB project with an Asian lead customer, shipped B-TRAN evaluation samples to Stellantis, and signed a long-term supply agreement with an Asian wafer foundry. Cash was $41.3M; net loss $3.4M.